Thiogenesis Therapeutics, Corp.
TTIPF
$0.44
$0.02897.03%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.45% | 3.21% | -5.34% | 6.35% | 98.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.92% | 45.48% | 68.62% | 150.65% | 76.17% |
| Operating Income | -18.92% | -45.48% | -68.62% | -150.65% | -76.17% |
| Income Before Tax | -17.89% | -43.64% | -70.17% | -22.57% | 14.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.89% | -43.64% | -70.17% | -22.57% | 14.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.89% | -43.64% | -70.17% | -22.57% | 14.84% |
| EBIT | -18.92% | -45.48% | -68.62% | -150.65% | -76.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -5.97% | -22.12% | -36.69% | 50.62% | 67.44% |
| Normalized Basic EPS | -7.26% | -23.59% | -38.27% | -52.96% | 13.05% |
| EPS Diluted | -5.97% | -22.12% | -36.69% | 50.62% | 67.44% |
| Normalized Diluted EPS | -7.26% | -23.59% | -38.27% | -52.96% | 13.05% |
| Average Basic Shares Outstanding | 17.08% | 21.24% | 26.98% | 54.99% | 88.90% |
| Average Diluted Shares Outstanding | 17.08% | 21.24% | 26.98% | 54.99% | 88.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |